Role of Ranolazine in the Prevention and Treatment of Atrial Fibrillation in Patients with Left Ventricular Systolic Dysfunction: A Meta-Analysis of Randomized Clinical Trials

• Type of Material: Article
• Authors: Pattranee Leelapatana, Chulalongkorn University and King Chulalongkorn Memorial Hospital; Charat Thongprayoon, Mayo Clinic, Rochester; Narut Prasitlumkum, University of California Riverside; Saraschandra Vallabhajosyula, Emory University; Wisit Cheungpasitporn, Mayo Clinic, Rochester; Ronpichai Chokesuwattanaskul, Chulalongkorn University and King Chulalongkorn Memorial Hospital
• Language: English
• Date: 2021-06-01
• Publisher: MDPI
• Publication Version: Final Published Version
• Copyright Statement: © 2021 by the authors.
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.3390/diseases9020031
• Title of Journal or Parent Work: Diseases
• Volume: 9
• Issue: 2
• Grant/Funding Information: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
• Keywords: systolic dysfunction; ranolazine; meta-analysis; atrial fibrillation; heart failure
• Research Categories: Health Sciences, Medicine and Surgery

Abstract

Background: Ranolazine has the potential to prevent atrial fibrillation (AF) and plays a role in rhythm control strategy for atrial fibrillation in various clinical settings. However, data on the use of ranolazine in patients with left ventricular (LV) systolic dysfunction are limited. The aims of this meta-analysis of randomized clinical trials are to investigate the efficacy and safety of ranolazine in AF patients with LV systolic dysfunction. PubMed and the Cochrane Database of Systematic Reviews were searched until July 2020. The efficacy outcomes included the incidence of new-onset AF, the rate of sinus rhythm restoration, and the time until sinus rhythm restoration. Safety endpoints were at death, and any adverse events were reported in the enrolled studies. We initially identified 204 studies and finally retrieved 5 RCTs. Three studies were analyzed in the meta-analysis. Among AF patients with LV systolic dysfunction, our meta-analysis showed that the combination of ranolazine to amiodarone significantly increased the sinus rhythm restoration rate compared to amiodarone alone (risk ratio (RR) 2.87, 95% confidence interval (CI) 2.48–3.32). Moreover, the time to sinus rhythm restoration was 2.46 h shorter in the ranolazine added to amiodarone group (95% CI: 2.27–2.64). No significant adverse events and proarrhythmias in the ranolazine group were identified. In conclusion, in AF patients with LV systolic dysfunction, ranolazine as an add-on therapy to amiodarone potentiates and accelerates the conversion of AF to sinus rhythm. Moreover, ranolazine shows good safety profiles. Further studies to investigate the effectiveness of ranolazine in the prevention of new-onset AF among patients with LV systolic dysfunction are needed.